Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Asthma | 31 | 2024 | 390 | 6.290 |
Why?
|
Pancreatic Neoplasms | 8 | 2024 | 69 | 5.120 |
Why?
|
Carcinoma, Pancreatic Ductal | 5 | 2023 | 20 | 3.860 |
Why?
|
Delivery of Health Care, Integrated | 6 | 2024 | 567 | 2.010 |
Why?
|
Middle Aged | 59 | 2024 | 8284 | 2.000 |
Why?
|
Male | 63 | 2024 | 10440 | 1.920 |
Why?
|
Severity of Illness Index | 11 | 2024 | 476 | 1.880 |
Why?
|
Female | 75 | 2024 | 13136 | 1.860 |
Why?
|
Aged | 42 | 2024 | 6417 | 1.850 |
Why?
|
Nitric Oxide | 4 | 2019 | 7 | 1.830 |
Why?
|
Humans | 87 | 2024 | 18430 | 1.810 |
Why?
|
Retrospective Studies | 36 | 2024 | 2550 | 1.800 |
Why?
|
Pancreatitis | 5 | 2019 | 49 | 1.660 |
Why?
|
Natural Language Processing | 6 | 2024 | 57 | 1.630 |
Why?
|
Adult | 54 | 2024 | 7910 | 1.490 |
Why?
|
Anti-Asthmatic Agents | 8 | 2019 | 85 | 1.420 |
Why?
|
Adolescent | 37 | 2024 | 3798 | 1.390 |
Why?
|
Young Adult | 32 | 2024 | 2518 | 1.360 |
Why?
|
California | 28 | 2024 | 2365 | 1.270 |
Why?
|
Aged, 80 and over | 14 | 2024 | 2003 | 1.200 |
Why?
|
Atrial Fibrillation | 6 | 2017 | 167 | 1.160 |
Why?
|
Stroke Volume | 2 | 2018 | 98 | 1.100 |
Why?
|
Risk Factors | 27 | 2024 | 3449 | 1.080 |
Why?
|
Diabetes Mellitus | 4 | 2020 | 530 | 1.080 |
Why?
|
Residence Characteristics | 3 | 2024 | 256 | 1.030 |
Why?
|
Pancreatitis, Chronic | 2 | 2023 | 18 | 1.030 |
Why?
|
Tomography, X-Ray Computed | 5 | 2023 | 208 | 1.000 |
Why?
|
Health Maintenance Organizations | 7 | 2016 | 479 | 0.970 |
Why?
|
Crime | 1 | 2024 | 21 | 0.950 |
Why?
|
Cough | 2 | 2020 | 22 | 0.920 |
Why?
|
Child | 21 | 2019 | 2571 | 0.900 |
Why?
|
Adrenal Cortex Hormones | 8 | 2018 | 72 | 0.900 |
Why?
|
Cause of Death | 3 | 2019 | 185 | 0.890 |
Why?
|
Mortality | 2 | 2019 | 123 | 0.860 |
Why?
|
Predictive Value of Tests | 11 | 2024 | 365 | 0.820 |
Why?
|
Brain Infarction | 1 | 2021 | 1 | 0.790 |
Why?
|
Leukoencephalopathies | 1 | 2021 | 1 | 0.790 |
Why?
|
Echocardiography | 2 | 2024 | 31 | 0.790 |
Why?
|
European Continental Ancestry Group | 3 | 2020 | 554 | 0.760 |
Why?
|
Triglycerides | 2 | 2018 | 87 | 0.760 |
Why?
|
Quality of Life | 4 | 2020 | 529 | 0.730 |
Why?
|
Asian Continental Ancestry Group | 2 | 2019 | 90 | 0.730 |
Why?
|
Cohort Studies | 14 | 2024 | 2672 | 0.720 |
Why?
|
Pancreatic Ducts | 1 | 2020 | 6 | 0.710 |
Why?
|
Gastroesophageal Reflux | 1 | 2020 | 79 | 0.680 |
Why?
|
Follow-Up Studies | 10 | 2024 | 1269 | 0.680 |
Why?
|
Magnetic Resonance Imaging | 1 | 2020 | 105 | 0.670 |
Why?
|
Glycated Hemoglobin A | 1 | 2020 | 233 | 0.650 |
Why?
|
Adrenergic beta-2 Receptor Agonists | 3 | 2015 | 6 | 0.640 |
Why?
|
Hypertriglyceridemia | 1 | 2018 | 13 | 0.630 |
Why?
|
Propensity Score | 2 | 2018 | 94 | 0.630 |
Why?
|
Analgesics, Opioid | 3 | 2019 | 241 | 0.600 |
Why?
|
Algorithms | 5 | 2024 | 241 | 0.590 |
Why?
|
Warfarin | 4 | 2017 | 73 | 0.580 |
Why?
|
Time Factors | 11 | 2024 | 1136 | 0.580 |
Why?
|
Hospitalization | 10 | 2019 | 847 | 0.560 |
Why?
|
Eosinophils | 5 | 2017 | 9 | 0.550 |
Why?
|
Sinusitis | 1 | 2016 | 14 | 0.550 |
Why?
|
Managed Care Programs | 7 | 2020 | 347 | 0.550 |
Why?
|
Stroke | 5 | 2017 | 311 | 0.540 |
Why?
|
Prognosis | 7 | 2020 | 624 | 0.540 |
Why?
|
Opioid-Related Disorders | 1 | 2019 | 168 | 0.540 |
Why?
|
Respiratory Tract Infections | 1 | 2016 | 54 | 0.530 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2018 | 182 | 0.530 |
Why?
|
Pregnancy Complications, Infectious | 2 | 2016 | 142 | 0.500 |
Why?
|
Anticoagulants | 3 | 2017 | 125 | 0.500 |
Why?
|
Incidence | 7 | 2021 | 1314 | 0.500 |
Why?
|
Anti-Bacterial Agents | 1 | 2016 | 142 | 0.480 |
Why?
|
Continental Population Groups | 6 | 2016 | 315 | 0.480 |
Why?
|
Breath Tests | 2 | 2011 | 8 | 0.480 |
Why?
|
Computer Simulation | 1 | 2014 | 85 | 0.470 |
Why?
|
Models, Theoretical | 1 | 2014 | 76 | 0.460 |
Why?
|
Community-Institutional Relations | 1 | 2014 | 47 | 0.460 |
Why?
|
Heart Failure | 2 | 2018 | 398 | 0.450 |
Why?
|
Adrenergic beta-Agonists | 4 | 2015 | 33 | 0.440 |
Why?
|
Child, Preschool | 12 | 2019 | 1478 | 0.440 |
Why?
|
Models, Statistical | 1 | 2014 | 185 | 0.430 |
Why?
|
Treatment Outcome | 6 | 2019 | 1296 | 0.420 |
Why?
|
Disease Progression | 8 | 2024 | 271 | 0.420 |
Why?
|
Machine Learning | 2 | 2023 | 44 | 0.420 |
Why?
|
Prevalence | 11 | 2018 | 911 | 0.410 |
Why?
|
Biomarkers | 4 | 2019 | 308 | 0.410 |
Why?
|
Emergency Service, Hospital | 6 | 2024 | 382 | 0.390 |
Why?
|
Risk Assessment | 5 | 2020 | 1143 | 0.390 |
Why?
|
Asian Americans | 2 | 2020 | 182 | 0.380 |
Why?
|
Ethnic Groups | 4 | 2010 | 501 | 0.380 |
Why?
|
Glucocorticoids | 1 | 2010 | 21 | 0.370 |
Why?
|
Antihypertensive Agents | 2 | 2018 | 172 | 0.360 |
Why?
|
Chronic Disease | 5 | 2020 | 468 | 0.360 |
Why?
|
Acute Disease | 7 | 2019 | 144 | 0.350 |
Why?
|
Kidney Failure, Chronic | 2 | 2024 | 151 | 0.340 |
Why?
|
Censuses | 2 | 2012 | 32 | 0.330 |
Why?
|
Odds Ratio | 7 | 2019 | 701 | 0.330 |
Why?
|
Age Factors | 7 | 2019 | 965 | 0.330 |
Why?
|
African Americans | 2 | 2020 | 490 | 0.330 |
Why?
|
United States | 9 | 2022 | 4164 | 0.330 |
Why?
|
Quality of Health Care | 3 | 2018 | 347 | 0.330 |
Why?
|
Surveys and Questionnaires | 5 | 2020 | 1389 | 0.320 |
Why?
|
Blood Glucose | 3 | 2024 | 346 | 0.320 |
Why?
|
Pregnancy | 11 | 2018 | 1516 | 0.310 |
Why?
|
Vaccines | 2 | 2022 | 222 | 0.300 |
Why?
|
Adrenergic beta-Antagonists | 2 | 2018 | 43 | 0.300 |
Why?
|
Drug Prescriptions | 4 | 2014 | 157 | 0.300 |
Why?
|
Intracranial Hemorrhages | 1 | 2007 | 16 | 0.300 |
Why?
|
Forced Expiratory Volume | 3 | 2012 | 69 | 0.290 |
Why?
|
Ventricular Function, Left | 2 | 2018 | 50 | 0.290 |
Why?
|
Socioeconomic Factors | 2 | 2024 | 673 | 0.280 |
Why?
|
Psychometrics | 3 | 2012 | 124 | 0.280 |
Why?
|
Prospective Studies | 5 | 2019 | 1314 | 0.280 |
Why?
|
Registries | 2 | 2020 | 490 | 0.280 |
Why?
|
Myocardial Infarction | 2 | 2005 | 249 | 0.270 |
Why?
|
Exhalation | 2 | 2019 | 2 | 0.260 |
Why?
|
Pancreas | 2 | 2023 | 14 | 0.260 |
Why?
|
Infant, Newborn | 6 | 2019 | 872 | 0.260 |
Why?
|
Breast Neoplasms | 4 | 2005 | 1037 | 0.250 |
Why?
|
Estrogen Replacement Therapy | 1 | 2005 | 104 | 0.250 |
Why?
|
Hypolipidemic Agents | 1 | 2005 | 44 | 0.250 |
Why?
|
Electronic Health Records | 4 | 2019 | 747 | 0.250 |
Why?
|
Reproducibility of Results | 4 | 2020 | 399 | 0.250 |
Why?
|
Waiting Lists | 1 | 2024 | 12 | 0.240 |
Why?
|
Heart Valve Diseases | 1 | 2024 | 20 | 0.240 |
Why?
|
Recurrence | 4 | 2018 | 187 | 0.240 |
Why?
|
Exercise Test | 1 | 2024 | 45 | 0.240 |
Why?
|
Small-Area Analysis | 1 | 2004 | 4 | 0.240 |
Why?
|
Kidney Transplantation | 1 | 2024 | 29 | 0.240 |
Why?
|
Hispanic Americans | 3 | 2020 | 428 | 0.230 |
Why?
|
Diverticulitis, Colonic | 2 | 2014 | 8 | 0.230 |
Why?
|
Social Determinants of Health | 1 | 2024 | 47 | 0.230 |
Why?
|
Neoplasm Staging | 2 | 2020 | 337 | 0.220 |
Why?
|
Databases, Factual | 4 | 2019 | 327 | 0.220 |
Why?
|
Administration, Inhalation | 3 | 2013 | 37 | 0.220 |
Why?
|
Infant | 6 | 2019 | 1245 | 0.220 |
Why?
|
Multivariate Analysis | 6 | 2017 | 598 | 0.210 |
Why?
|
Shoulder Injuries | 1 | 2022 | 2 | 0.210 |
Why?
|
Length of Stay | 3 | 2019 | 183 | 0.200 |
Why?
|
Practice Patterns, Physicians' | 1 | 2005 | 350 | 0.200 |
Why?
|
Overweight | 2 | 2015 | 276 | 0.200 |
Why?
|
Hypersensitivity, Immediate | 2 | 2011 | 5 | 0.190 |
Why?
|
Diabetes, Gestational | 4 | 2009 | 339 | 0.190 |
Why?
|
Leukocyte Count | 3 | 2017 | 22 | 0.190 |
Why?
|
Self Report | 2 | 2020 | 256 | 0.190 |
Why?
|
Multiple Organ Failure | 2 | 2017 | 12 | 0.190 |
Why?
|
Drug Therapy, Combination | 2 | 2019 | 119 | 0.180 |
Why?
|
Sex Factors | 3 | 2019 | 661 | 0.180 |
Why?
|
Patient Reported Outcome Measures | 1 | 2020 | 54 | 0.180 |
Why?
|
Comorbidity | 6 | 2017 | 619 | 0.180 |
Why?
|
Dilatation, Pathologic | 1 | 2020 | 2 | 0.180 |
Why?
|
Data Warehousing | 1 | 2020 | 3 | 0.180 |
Why?
|
Glycemic Index | 1 | 2020 | 21 | 0.180 |
Why?
|
Fetal Macrosomia | 1 | 2000 | 27 | 0.180 |
Why?
|
Anaphylaxis | 1 | 2019 | 15 | 0.170 |
Why?
|
Vaccination | 2 | 2022 | 674 | 0.170 |
Why?
|
Proton Pump Inhibitors | 1 | 2020 | 25 | 0.170 |
Why?
|
Hypertension | 3 | 2017 | 524 | 0.170 |
Why?
|
Pregnancy Complications, Cardiovascular | 2 | 2017 | 27 | 0.170 |
Why?
|
Early Ambulation | 1 | 2019 | 3 | 0.170 |
Why?
|
Bronchodilator Agents | 1 | 2019 | 21 | 0.160 |
Why?
|
Eating | 1 | 2019 | 38 | 0.160 |
Why?
|
Analgesics | 1 | 2019 | 28 | 0.160 |
Why?
|
Delivery of Health Care | 3 | 2019 | 444 | 0.160 |
Why?
|
Pain Management | 1 | 2019 | 59 | 0.160 |
Why?
|
Fetal Growth Retardation | 1 | 2018 | 11 | 0.160 |
Why?
|
Disease Management | 1 | 2019 | 143 | 0.160 |
Why?
|
Diphtheria-Tetanus-acellular Pertussis Vaccines | 1 | 2019 | 95 | 0.150 |
Why?
|
Birth Certificates | 2 | 2010 | 22 | 0.150 |
Why?
|
Longitudinal Studies | 2 | 2018 | 724 | 0.150 |
Why?
|
Body Mass Index | 6 | 2020 | 974 | 0.150 |
Why?
|
Pregnancy Outcome | 3 | 2016 | 159 | 0.150 |
Why?
|
Survival Rate | 1 | 2018 | 269 | 0.150 |
Why?
|
Drug Utilization | 2 | 2017 | 134 | 0.150 |
Why?
|
Febrile Neutropenia | 1 | 2017 | 3 | 0.150 |
Why?
|
Quality Assurance, Health Care | 1 | 2018 | 188 | 0.140 |
Why?
|
Patient Discharge | 1 | 2019 | 153 | 0.140 |
Why?
|
Heart Defects, Congenital | 1 | 2017 | 37 | 0.140 |
Why?
|
Blood Cells | 1 | 2016 | 4 | 0.140 |
Why?
|
Research Design | 1 | 2019 | 402 | 0.140 |
Why?
|
Renal Dialysis | 1 | 2017 | 59 | 0.140 |
Why?
|
Insurance, Health | 1 | 2018 | 217 | 0.140 |
Why?
|
Atrial Flutter | 1 | 2016 | 15 | 0.140 |
Why?
|
Ambulatory Care | 2 | 2014 | 266 | 0.130 |
Why?
|
Diverticulitis | 1 | 2014 | 2 | 0.120 |
Why?
|
Eosinophilia | 1 | 2014 | 2 | 0.120 |
Why?
|
Tamoxifen | 2 | 2005 | 60 | 0.120 |
Why?
|
Treatment Failure | 2 | 2015 | 36 | 0.120 |
Why?
|
Likelihood Functions | 1 | 2014 | 48 | 0.120 |
Why?
|
Poisson Distribution | 1 | 2014 | 94 | 0.120 |
Why?
|
Inpatients | 1 | 2014 | 80 | 0.120 |
Why?
|
Outpatients | 1 | 2014 | 111 | 0.120 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2015 | 199 | 0.110 |
Why?
|
Cluster Analysis | 1 | 2013 | 96 | 0.110 |
Why?
|
Phenotype | 1 | 2013 | 148 | 0.110 |
Why?
|
Seasons | 1 | 2013 | 105 | 0.110 |
Why?
|
Lung | 1 | 2013 | 62 | 0.110 |
Why?
|
Health Care Costs | 1 | 2015 | 251 | 0.110 |
Why?
|
Health Surveys | 2 | 2011 | 269 | 0.110 |
Why?
|
Chorioamnionitis | 2 | 2010 | 18 | 0.110 |
Why?
|
Sex Distribution | 3 | 2013 | 198 | 0.110 |
Why?
|
Patient Selection | 2 | 2012 | 198 | 0.100 |
Why?
|
Rhinitis | 1 | 2012 | 2 | 0.100 |
Why?
|
Cross-Sectional Studies | 3 | 2015 | 1360 | 0.100 |
Why?
|
Medication Adherence | 1 | 2015 | 267 | 0.100 |
Why?
|
Practice Guidelines as Topic | 2 | 2015 | 333 | 0.100 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 1 | 2013 | 70 | 0.100 |
Why?
|
Age Distribution | 2 | 2013 | 261 | 0.100 |
Why?
|
Inflammation | 1 | 2011 | 63 | 0.090 |
Why?
|
Abdominal Pain | 3 | 2017 | 15 | 0.090 |
Why?
|
Vital Capacity | 1 | 2010 | 35 | 0.090 |
Why?
|
International Normalized Ratio | 2 | 2008 | 22 | 0.090 |
Why?
|
African Continental Ancestry Group | 2 | 2012 | 166 | 0.090 |
Why?
|
Databases as Topic | 1 | 2010 | 22 | 0.090 |
Why?
|
Medical Records Systems, Computerized | 1 | 2010 | 95 | 0.090 |
Why?
|
Body Height | 1 | 2010 | 62 | 0.090 |
Why?
|
Gestational Age | 4 | 2017 | 119 | 0.090 |
Why?
|
Glucose Intolerance | 1 | 2009 | 45 | 0.090 |
Why?
|
Logistic Models | 4 | 2017 | 962 | 0.090 |
Why?
|
Health Services | 1 | 2010 | 117 | 0.090 |
Why?
|
Stillbirth | 1 | 2009 | 30 | 0.080 |
Why?
|
Postpartum Period | 1 | 2009 | 93 | 0.080 |
Why?
|
Body Weight | 1 | 2010 | 223 | 0.080 |
Why?
|
Rhinitis, Allergic, Perennial | 1 | 2008 | 3 | 0.080 |
Why?
|
Propranolol | 2 | 2018 | 4 | 0.080 |
Why?
|
Metoprolol | 2 | 2018 | 6 | 0.080 |
Why?
|
Atenolol | 2 | 2018 | 8 | 0.080 |
Why?
|
Labetalol | 2 | 2018 | 9 | 0.080 |
Why?
|
Glucose Tolerance Test | 2 | 2009 | 106 | 0.080 |
Why?
|
Cost of Illness | 1 | 2008 | 100 | 0.080 |
Why?
|
Antineoplastic Agents, Hormonal | 2 | 2005 | 65 | 0.070 |
Why?
|
Obesity | 2 | 2013 | 855 | 0.070 |
Why?
|
Proportional Hazards Models | 2 | 2020 | 743 | 0.070 |
Why?
|
Progestins | 1 | 2005 | 28 | 0.060 |
Why?
|
Medical Record Linkage | 1 | 2005 | 44 | 0.060 |
Why?
|
Benzothiadiazines | 1 | 2005 | 2 | 0.060 |
Why?
|
Adrenergic alpha-Antagonists | 1 | 2005 | 9 | 0.060 |
Why?
|
Sodium Chloride Symporter Inhibitors | 1 | 2005 | 9 | 0.060 |
Why?
|
Publishing | 1 | 2005 | 9 | 0.060 |
Why?
|
Diuretics | 1 | 2005 | 17 | 0.060 |
Why?
|
Paroxetine | 1 | 2005 | 23 | 0.060 |
Why?
|
Survival Analysis | 1 | 2005 | 226 | 0.060 |
Why?
|
Myocardial Perfusion Imaging | 1 | 2024 | 2 | 0.060 |
Why?
|
Health Status | 3 | 2013 | 328 | 0.060 |
Why?
|
Preoperative Care | 1 | 2024 | 19 | 0.060 |
Why?
|
Risk | 2 | 2017 | 552 | 0.060 |
Why?
|
Public Health Informatics | 1 | 2004 | 8 | 0.060 |
Why?
|
Epidemiologic Studies | 1 | 2004 | 32 | 0.060 |
Why?
|
Geography | 1 | 2004 | 41 | 0.060 |
Why?
|
Cultural Diversity | 1 | 2004 | 17 | 0.060 |
Why?
|
Leukocytosis | 2 | 2014 | 5 | 0.060 |
Why?
|
Medical Records | 1 | 2004 | 106 | 0.060 |
Why?
|
Antidepressive Agents | 1 | 2005 | 162 | 0.060 |
Why?
|
Sensitivity and Specificity | 2 | 2020 | 321 | 0.060 |
Why?
|
Fever | 2 | 2014 | 60 | 0.060 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2005 | 342 | 0.060 |
Why?
|
Los Angeles | 2 | 2019 | 141 | 0.050 |
Why?
|
Drug Utilization Review | 2 | 2013 | 26 | 0.050 |
Why?
|
Blindness | 1 | 2002 | 5 | 0.050 |
Why?
|
Income | 2 | 2013 | 98 | 0.050 |
Why?
|
Case-Control Studies | 3 | 2015 | 1173 | 0.050 |
Why?
|
Diabetic Retinopathy | 1 | 2002 | 19 | 0.050 |
Why?
|
Data Collection | 2 | 2013 | 275 | 0.050 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2020 | 11 | 0.050 |
Why?
|
Birth Injuries | 1 | 2000 | 1 | 0.050 |
Why?
|
Brachial Plexus | 1 | 2000 | 1 | 0.050 |
Why?
|
Dystocia | 1 | 2000 | 1 | 0.050 |
Why?
|
Shoulder | 1 | 2000 | 1 | 0.050 |
Why?
|
Ultrasonography, Prenatal | 1 | 2000 | 8 | 0.040 |
Why?
|
Kaplan-Meier Estimate | 1 | 2020 | 131 | 0.040 |
Why?
|
Prenatal Diagnosis | 1 | 2000 | 18 | 0.040 |
Why?
|
Obstetrics | 1 | 2000 | 23 | 0.040 |
Why?
|
Patient Readmission | 2 | 2019 | 162 | 0.040 |
Why?
|
Diabetes Complications | 1 | 2020 | 119 | 0.040 |
Why?
|
Fasting | 1 | 1999 | 48 | 0.040 |
Why?
|
Food | 1 | 1999 | 31 | 0.040 |
Why?
|
Transportation of Patients | 1 | 1999 | 4 | 0.040 |
Why?
|
Recovery of Function | 1 | 2019 | 28 | 0.040 |
Why?
|
Double-Blind Method | 1 | 2019 | 165 | 0.040 |
Why?
|
Patient Transfer | 1 | 1999 | 24 | 0.040 |
Why?
|
Combined Modality Therapy | 1 | 2019 | 150 | 0.040 |
Why?
|
Cardiovascular Diseases | 1 | 2024 | 630 | 0.040 |
Why?
|
Infant, Small for Gestational Age | 1 | 2018 | 59 | 0.040 |
Why?
|
Whooping Cough | 1 | 2019 | 75 | 0.040 |
Why?
|
Critical Care | 1 | 1999 | 73 | 0.040 |
Why?
|
Eclampsia | 1 | 2017 | 12 | 0.040 |
Why?
|
Smoking | 1 | 2020 | 494 | 0.040 |
Why?
|
Systemic Inflammatory Response Syndrome | 1 | 2017 | 9 | 0.040 |
Why?
|
Delphi Technique | 1 | 2017 | 33 | 0.040 |
Why?
|
Arrhythmias, Cardiac | 1 | 2017 | 32 | 0.040 |
Why?
|
Hyperlipidemias | 1 | 2017 | 58 | 0.040 |
Why?
|
Cell Count | 1 | 2016 | 10 | 0.040 |
Why?
|
Pre-Eclampsia | 1 | 2017 | 38 | 0.040 |
Why?
|
Hemorrhage | 1 | 2017 | 63 | 0.040 |
Why?
|
Pregnancy Trimesters | 1 | 2016 | 29 | 0.030 |
Why?
|
Emergency Medical Services | 1 | 2015 | 47 | 0.030 |
Why?
|
International Classification of Diseases | 1 | 2015 | 87 | 0.030 |
Why?
|
Pregnancy Complications | 1 | 2017 | 193 | 0.030 |
Why?
|
Outcome Assessment (Health Care) | 1 | 2015 | 254 | 0.030 |
Why?
|
Pilot Projects | 1 | 2014 | 237 | 0.030 |
Why?
|
Health Resources | 1 | 2013 | 38 | 0.030 |
Why?
|
Chi-Square Distribution | 1 | 2013 | 160 | 0.030 |
Why?
|
Health Status Indicators | 1 | 2013 | 71 | 0.030 |
Why?
|
Analysis of Variance | 1 | 2013 | 167 | 0.030 |
Why?
|
Pharmaceutical Services | 1 | 2013 | 37 | 0.030 |
Why?
|
Abscess | 1 | 2012 | 6 | 0.030 |
Why?
|
Health Care Surveys | 1 | 2013 | 247 | 0.030 |
Why?
|
Regression Analysis | 1 | 2013 | 319 | 0.030 |
Why?
|
Process Assessment (Health Care) | 1 | 2012 | 28 | 0.030 |
Why?
|
Family Characteristics | 1 | 2012 | 54 | 0.020 |
Why?
|
Educational Status | 1 | 2012 | 205 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2012 | 133 | 0.020 |
Why?
|
Health Planning | 1 | 2010 | 17 | 0.020 |
Why?
|
Quality Control | 1 | 2010 | 48 | 0.020 |
Why?
|
Poverty | 1 | 2012 | 182 | 0.020 |
Why?
|
Catchment Area (Health) | 1 | 2010 | 8 | 0.020 |
Why?
|
Health Services Research | 1 | 2012 | 264 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2010 | 253 | 0.020 |
Why?
|
Fetal Diseases | 1 | 2010 | 8 | 0.020 |
Why?
|
Fetal Membranes, Premature Rupture | 1 | 2010 | 11 | 0.020 |
Why?
|
Maternal Age | 1 | 2010 | 80 | 0.020 |
Why?
|
Fetal Distress | 1 | 2009 | 4 | 0.020 |
Why?
|
Conjunctivitis | 1 | 2008 | 2 | 0.020 |
Why?
|
Sleep Apnea Syndromes | 1 | 2008 | 8 | 0.020 |
Why?
|
Otitis Media | 1 | 2008 | 21 | 0.020 |
Why?
|
Fatigue | 1 | 2008 | 35 | 0.020 |
Why?
|
Healthcare Disparities | 1 | 2010 | 211 | 0.020 |
Why?
|
Models, Economic | 1 | 2008 | 22 | 0.020 |
Why?
|
Pharmacogenetics | 1 | 2008 | 15 | 0.020 |
Why?
|
Group Practice | 1 | 2008 | 26 | 0.020 |
Why?
|
Probability | 1 | 2008 | 86 | 0.020 |
Why?
|
Radiotherapy | 1 | 2005 | 4 | 0.020 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2005 | 73 | 0.020 |
Why?
|
Estrogen Antagonists | 1 | 2004 | 3 | 0.020 |
Why?
|
Selective Estrogen Receptor Modulators | 1 | 2004 | 12 | 0.020 |
Why?
|
False Positive Reactions | 1 | 2003 | 26 | 0.010 |
Why?
|
ROC Curve | 1 | 2003 | 83 | 0.010 |
Why?
|
Vitrectomy | 1 | 2002 | 1 | 0.010 |
Why?
|
Laser Coagulation | 1 | 2002 | 2 | 0.010 |
Why?
|
Visual Acuity | 1 | 2002 | 22 | 0.010 |
Why?
|
Prenatal Care | 1 | 2003 | 134 | 0.010 |
Why?
|
3-Hydroxybutyric Acid | 1 | 1999 | 1 | 0.010 |
Why?
|
Kinetics | 1 | 1999 | 12 | 0.010 |
Why?
|
Fatty Acids, Nonesterified | 1 | 1999 | 12 | 0.010 |
Why?
|
Hydrocortisone | 1 | 1999 | 16 | 0.010 |
Why?
|
Diagnosis-Related Groups | 1 | 1999 | 27 | 0.010 |
Why?
|
Insulin | 1 | 1999 | 208 | 0.010 |
Why?
|
Hospital Mortality | 1 | 1999 | 150 | 0.010 |
Why?
|
Mass Screening | 1 | 2003 | 690 | 0.010 |
Why?
|